Christopher Palmer has been an associate editor at MDedge News since 2017. When he's not tidying grammar, he writes short pieces about breaking FDA announcements and approvals, as well as journal articles. He proudly holds a BA in English and philosophy. Follow him on Twitter @cmacmpalm.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA approves omadacycline for pneumonia and skin infections
- Author:
- Christopher Palmer
The tetracycline antibiotic was approved for CABP and acute bacterial skin and skin structure infections in adults.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA approves Arikayce for MAC lung diseases
- Author:
- Christopher Palmer
This is the first time a drug has been approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs.
News
Adalimumab safety update finds no new signals
- Author:
- Christopher Palmer
The new integrated analysis includes safety data from five clinical trials that were not included in the analysis from 2009.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/May-2018/NICU_web.jpg)
Methadone may shorten NICU stays for neonatal abstinence syndrome
- Author:
- Christopher Palmer
The shorter LOS with methadone vs. morphine could have relevance to clinical practice, given the increasing...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/September-2018/driver_teen_web.jpg)
New AAP policy statement addresses teen driver risks
- Author:
- Christopher Palmer
There are many risk factors unique to teen drivers, but the AAP policy statement puts forward interventions to...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/October-2018/alz_graphic_0.jpg)
Burden of dementia will shift more to minorities by 2060
- Author:
- Christopher Palmer
More culturally competent and appropriate interventions may be required.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA clears gold microparticles for acne vulgaris
- Author:
- Christopher Palmer
These microparticles are designed to work with laser therapy to improve responses to treatment.
News
ICYMI: Canakinumab reduced risk of gout attacks
- Author:
- Christopher Palmer
Previous analysis of CANTOS data showed canakinumab shortened the length of gout attacks.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA approves device for coronary artery perforations
- Author:
- Christopher Palmer
This is the first device approved for acute coronary artery perforations in 17 years.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
FDA grants praliciguat Fast Track Designation for HFpEF
- Author:
- Christopher Palmer
Enrollment for a phase 2 trial in HFpEF patients continues.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/FDA_icon3_web.jpg)
Subcutaneous Actemra approved for systemic JIA
- Author:
- Christopher Palmer
The safety profile was fairly similar to that seen with intravenous formulations.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/May-2018/Lawrence_Hal_WASH_DC_web.jpg)
Dr. Hal C. Lawrence III retires from ACOG
- Author:
- Christopher Palmer
Dr. Lawrence had been with ACOG for 11 years and been the EVP and CEO for 7 years.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Zika_Virus_web.jpg)
Screen all infants exposed to Zika for eye abnormalities, study suggests
- Author:
- Christopher Palmer
Although the correlation was high between CNS abnormalities and opthalmic abnormalities, there were exceptions.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/Image/March-2018/Kratom_tree_web.jpg)
FDA warns kratom vendors about unproven claims
- Author:
- Christopher Palmer
The substance is already outlawed in several countries and banned in some states.
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/articles/hemtimes/follicular-lymphoma-230.jpg)
Regimens produce similar results in FL
- Author:
- Christopher Palmer
Rituximab plus lenalidomide had efficacy similar to that of rituximab plus chemotherapy in the treatment of follicular lymphoma (FL) in a phase 3...